Granules India Limited (GRANULES.BO)
INR 600.35
(0.58%)
INR 600.35
(0.58%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 4.05 Billion INR | -21.54% |
| 2022 | 5.16 Billion INR | 25.16% |
| 2021 | 4.12 Billion INR | -24.88% |
| 2020 | 5.49 Billion INR | 63.82% |
| 2019 | 3.35 Billion INR | 41.87% |
| 2018 | 2.36 Billion INR | 78.3% |
| 2017 | 1.32 Billion INR | -19.41% |
| 2016 | 1.64 Billion INR | 33.75% |
| 2015 | 1.23 Billion INR | 35.3% |
| 2014 | 909.07 Million INR | 20.84% |
| 2013 | 752.31 Million INR | 131.0% |
| 2012 | 325.67 Million INR | 8.73% |
| 2011 | 299.52 Million INR | 43.34% |
| 2010 | 208.95 Million INR | -31.2% |
| 2009 | 303.71 Million INR | 0.0% |
| 2008 | - INR | -100.0% |
| 2007 | 90.04 Million INR | 18.54% |
| 2006 | 75.96 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.34 Billion INR | 3.86% |
| 2023 Q4 | 1.29 Billion INR | 3.18% |
| 2023 Q3 | 1.25 Billion INR | 23.05% |
| 2023 FY | 4.05 Billion INR | -21.54% |
| 2023 Q1 | 478.95 Million INR | -59.96% |
| 2023 Q2 | 1.02 Billion INR | 113.21% |
| 2022 Q4 | 1.19 Billion INR | -3.8% |
| 2022 Q3 | 1.24 Billion INR | -14.31% |
| 2022 FY | 5.16 Billion INR | 25.16% |
| 2022 Q1 | 1.27 Billion INR | 14.93% |
| 2022 Q2 | 1.45 Billion INR | 13.74% |
| 2021 Q4 | 1.1 Billion INR | 10.03% |
| 2021 Q1 | 1.2 Billion INR | -5.77% |
| 2021 FY | 4.12 Billion INR | -24.88% |
| 2021 Q3 | 1 Billion INR | 25.04% |
| 2021 Q2 | 806.78 Million INR | -32.88% |
| 2020 Q1 | 1.11 Billion INR | 20.7% |
| 2020 Q2 | 1.63 Billion INR | 46.82% |
| 2020 Q4 | 1.27 Billion INR | -13.1% |
| 2020 FY | 5.49 Billion INR | 63.82% |
| 2020 Q3 | 1.46 Billion INR | -10.28% |
| 2019 Q4 | 923.36 Million INR | 44.22% |
| 2019 Q1 | 832.41 Million INR | 29.99% |
| 2019 Q3 | 640.26 Million INR | -33.16% |
| 2019 Q2 | 957.93 Million INR | 15.08% |
| 2019 FY | 3.35 Billion INR | 41.87% |
| 2018 Q3 | 603.15 Million INR | 0.09% |
| 2018 FY | 2.36 Billion INR | 78.3% |
| 2018 Q1 | 517.95 Million INR | 153.42% |
| 2018 Q2 | 602.6 Million INR | 16.34% |
| 2018 Q4 | 640.36 Million INR | 6.17% |
| 2017 Q1 | 368.01 Million INR | -19.42% |
| 2017 FY | 1.32 Billion INR | -19.41% |
| 2017 Q4 | 204.38 Million INR | -41.63% |
| 2017 Q3 | 350.15 Million INR | -13.19% |
| 2017 Q2 | 403.36 Million INR | 9.61% |
| 2016 FY | 1.64 Billion INR | 33.75% |
| 2016 Q4 | 456.73 Million INR | 16.93% |
| 2016 Q3 | 390.61 Million INR | -4.32% |
| 2016 Q2 | 408.24 Million INR | 4.78% |
| 2016 Q1 | 389.6 Million INR | 18.11% |
| 2015 FY | 1.23 Billion INR | 35.3% |
| 2015 Q4 | 329.86 Million INR | 12.95% |
| 2015 Q2 | 322.74 Million INR | 13.1% |
| 2015 Q1 | 285.35 Million INR | 27.41% |
| 2015 Q3 | 292.04 Million INR | -9.51% |
| 2014 Q4 | 223.97 Million INR | -4.95% |
| 2014 Q3 | 235.64 Million INR | 6.72% |
| 2014 Q2 | 220.8 Million INR | -3.44% |
| 2014 FY | 909.07 Million INR | 20.84% |
| 2014 Q1 | 228.66 Million INR | -3.21% |
| 2013 Q3 | 218.05 Million INR | 44.33% |
| 2013 Q4 | 236.25 Million INR | 8.35% |
| 2013 Q2 | 151.08 Million INR | 2.83% |
| 2013 Q1 | 146.92 Million INR | 18.37% |
| 2013 FY | 752.31 Million INR | 131.0% |
| 2012 Q3 | 58.05 Million INR | -28.13% |
| 2012 Q4 | 124.12 Million INR | 113.83% |
| 2012 FY | 325.67 Million INR | 8.73% |
| 2012 Q1 | 62.72 Million INR | 0.0% |
| 2012 Q2 | 80.77 Million INR | 28.77% |
| 2011 FY | 299.52 Million INR | 43.34% |
| 2010 FY | 208.95 Million INR | -31.2% |
| 2009 FY | 303.71 Million INR | 0.0% |
| 2008 FY | - INR | -100.0% |
| 2007 FY | 90.04 Million INR | 18.54% |
| 2006 FY | 75.96 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Ajanta Pharma Limited | 8.16 Billion INR | 50.34% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -801.238% |
| Sigachi Industries Limited | 571.8 Million INR | -608.829% |
| Bal Pharma Limited | 73.92 Million INR | -5382.941% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 3.718% |
| Medico Remedies Limited | 82.9 Million INR | -4788.613% |
| Lasa Supergenerics Limited | -217.3 Million INR | 1965.158% |
| Venus Remedies Limited | 284.9 Million INR | -1322.6% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 204.673% |
| Alpa Laboratories Limited | 167.76 Million INR | -2315.939% |
| Nectar Lifesciences Limited | 49.95 Million INR | -8014.314% |
| Shilpa Medicare Limited | 318.74 Million INR | -1171.593% |
| Aarti Drugs Limited | 1.71 Billion INR | -136.445% |
| Lupin Limited | 19.14 Billion INR | 78.829% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 87.226% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 89.498% |
| Windlas Biotech Limited | 581.87 Million INR | -596.565% |
| Suven Life Sciences Limited | -1.05 Billion INR | 485.729% |
| Eris Lifesciences Limited | 3.91 Billion INR | -3.4% |
| Valiant Laboratories Limited | 3.19 Million INR | -126717.897% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 26.658% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 171.434% |
| Ipca Laboratories Limited | 5.47 Billion INR | 25.95% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -437.161% |
| Achyut Healthcare Limited | 5.73 Million INR | -70610.049% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 95.768% |
| Bajaj HealthCare Limited | -837.93 Million INR | 583.703% |
| RPG Life Sciences Limited | 876.6 Million INR | -362.366% |
| Mankind Pharma Limited | 19.12 Billion INR | 78.812% |
| Laurus Labs Limited | 1.6 Billion INR | -152.451% |
| Piramal Pharma Limited | 178.2 Million INR | -2174.467% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -1501.117% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 75.53% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 34.184% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 126.991% |
| Unichem Laboratories Limited | -704.74 Million INR | 675.117% |
| Sequent Scientific Limited | -358.69 Million INR | 1229.973% |
| Novartis India Limited | 851.9 Million INR | -375.772% |
| Wanbury Limited | 559.56 Million INR | -624.333% |
| Suven Pharmaceuticals Limited | 3 Billion INR | -34.977% |
| Wockhardt Limited | -4.63 Billion INR | 187.54% |
| Themis Medicare Limited | 435.23 Million INR | -831.238% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -1704.345% |
| Jubilant Pharmova Limited | 771 Million INR | -425.694% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 13.926% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 92.721% |
| Divi's Laboratories Limited | 16 Billion INR | 74.668% |
| NATCO Pharma Limited | 13.88 Billion INR | 70.805% |
| Gufic Biosciences Limited | 861.35 Million INR | -370.549% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -201.503% |
| Ind-Swift Limited | 142.31 Million INR | -2748.018% |
| Procter & Gamble Health Limited | 2 Billion INR | -101.667% |
| FDC Limited | 3.05 Billion INR | -32.791% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 2154.449% |
| Medicamen Biotech Limited | 109.31 Million INR | -3607.895% |
| Alkem Laboratories Limited | 17.95 Billion INR | 77.43% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -150.95% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -57050.31% |
| Brooks Laboratories Limited | -195.91 Million INR | 2168.763% |
| Megasoft Limited | -127.46 Million INR | 3279.75% |
| ZIM Laboratories Limited | 172.46 Million INR | -2250.114% |
| Strides Pharma Science Limited | -706.14 Million INR | 673.98% |
| Neuland Laboratories Limited | 3 Billion INR | -35.068% |
| Morepen Laboratories Limited | 961.59 Million INR | -321.496% |
| Hikal Limited | 696.02 Million INR | -482.325% |
| Indoco Remedies Limited | 984.6 Million INR | -311.649% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | -86.863% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -2675.83% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 4567.851% |
| Hester Biosciences Limited | 188.89 Million INR | -2045.746% |